Search

Displaying results 5941 - 5950 of 6198 in total
  1. Drug

    KOS-2187

    go.drugbank.com/drugs/DB05946
    Experimental

    KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease (GERD).

  2. Drug

    Nicaraven

    go.drugbank.com/drugs/DB06397
    Experimental

  3. Drug

    DDP-225

    go.drugbank.com/drugs/DB05642
    Investigational

    DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system. The uniq...

  4. Drug

    KBP-COVID-19

    go.drugbank.com/drugs/DB15858
    Investigational

    The KBP-201 COVID-19 Vaccine was developed by British American Tobacco’s (BAT) U.S. biotech subsidiary, Kentucky BioProcessing (KBP).

  5. Target

    Cyclin-dependent kinases

    go.drugbank.com/bio_entities/BE0010231
    TargetHumans

    Can phosphorylate CCNY at 'Ser-336' (in vitro) … The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro (PubMed:21127351).

    Synonyms: CAK, CAK-kinase p42
  6. Drug

    Telcagepant

    go.drugbank.com/drugs/DB12228
    Investigational

    It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine.

  7. Drug

    CX516

    go.drugbank.com/drugs/DB06247
    Investigational

  8. Drug

    G4460

    go.drugbank.com/drugs/DB06359
    Investigational

  9. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously.

  10. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease